Francesco Bertolini

Summary

Affiliation: European Institute of Oncology
Country: Italy

Publications

  1. ncbi request reprint Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer
    Silvia Dellapasqua
    Medical Senology Research Unit and Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    J Clin Oncol 26:4899-905. 2008
  2. ncbi request reprint Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy
    Raquel Munoz
    Sunnybrook and Women s College Health Sciences Centre, S 217, 2075 Bayview Avenue, Toronto, ONT Canada, M4N 3M5
    Breast 14:466-79. 2005
  3. ncbi request reprint Circulating endothelial progenitor cells
    Francesco Bertolini
    N Engl J Med 353:2613-6; author reply 2613-6. 2005
  4. ncbi request reprint High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma
    Rena Buckstein
    Medical Oncology, Toronto Sunnybrook Regional Cancer Centre, Sunnybrook and Women s College, Medical Oncology, Princess Margaret Hospital, Ontario, Canada
    Clin Cancer Res 12:5190-8. 2006
  5. ncbi request reprint Adipose tissue and breast cancer progression: a link between metabolism and cancer
    Francesco Bertolini
    Laboratory of Hematology Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy Electronic address
    Breast 22:S48-9. 2013
  6. doi request reprint Adipose tissue cells, lipotransfer and cancer: a challenge for scientists, oncologists and surgeons
    Francesco Bertolini
    Laboratory of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Biochim Biophys Acta 1826:209-14. 2012
  7. doi request reprint Contribution of endothelial precursors of adipose tissue to breast cancer: progression-link with fat graft for reconstructive surgery
    Francesco Bertolini
    Departments of Pathology and Medecine, Laboratory of Hematology Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Ann Endocrinol (Paris) 74:106-7. 2013
  8. doi request reprint Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer
    Francesco Bertolini
    Laboratory of Hematology Oncology and Department of Experimental Oncology, European Institute of Oncology, 20141 Milan, Italy
    Drug Discov Today 16:1052-60. 2011
  9. ncbi request reprint Anti-angiogenesis in cancer; met and unmet goals - an interview with Robert Kerbel
    Francesco Bertolini
    Laboratory of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Int J Dev Biol 55:395-8. 2011
  10. ncbi request reprint Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers
    F Bertolini
    Division of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 12:987-90. 2001

Detail Information

Publications97

  1. ncbi request reprint Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer
    Silvia Dellapasqua
    Medical Senology Research Unit and Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    J Clin Oncol 26:4899-905. 2008
    ..Metronomic chemotherapy has shown efficacy in patients with metastatic breast cancer. When used in association with targeted antiangiogenic drugs, it was more active than metronomic therapy alone in preclinical and clinical studies...
  2. ncbi request reprint Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy
    Raquel Munoz
    Sunnybrook and Women s College Health Sciences Centre, S 217, 2075 Bayview Avenue, Toronto, ONT Canada, M4N 3M5
    Breast 14:466-79. 2005
    ....
  3. ncbi request reprint Circulating endothelial progenitor cells
    Francesco Bertolini
    N Engl J Med 353:2613-6; author reply 2613-6. 2005
  4. ncbi request reprint High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma
    Rena Buckstein
    Medical Oncology, Toronto Sunnybrook Regional Cancer Centre, Sunnybrook and Women s College, Medical Oncology, Princess Margaret Hospital, Ontario, Canada
    Clin Cancer Res 12:5190-8. 2006
    ..Angiogenesis is increased in aggressive histology non-Hodgkin's lymphoma and may be a target with selective cyclooxygenase-2 inhibition and metronomic chemotherapy...
  5. ncbi request reprint Adipose tissue and breast cancer progression: a link between metabolism and cancer
    Francesco Bertolini
    Laboratory of Hematology Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy Electronic address
    Breast 22:S48-9. 2013
    ....
  6. doi request reprint Adipose tissue cells, lipotransfer and cancer: a challenge for scientists, oncologists and surgeons
    Francesco Bertolini
    Laboratory of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Biochim Biophys Acta 1826:209-14. 2012
    ....
  7. doi request reprint Contribution of endothelial precursors of adipose tissue to breast cancer: progression-link with fat graft for reconstructive surgery
    Francesco Bertolini
    Departments of Pathology and Medecine, Laboratory of Hematology Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Ann Endocrinol (Paris) 74:106-7. 2013
    ..This raises the issue of lipotransfer in patients undergoing plastic or reconstructive surgery...
  8. doi request reprint Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer
    Francesco Bertolini
    Laboratory of Hematology Oncology and Department of Experimental Oncology, European Institute of Oncology, 20141 Milan, Italy
    Drug Discov Today 16:1052-60. 2011
    ....
  9. ncbi request reprint Anti-angiogenesis in cancer; met and unmet goals - an interview with Robert Kerbel
    Francesco Bertolini
    Laboratory of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Int J Dev Biol 55:395-8. 2011
    ..In this interview, Dr. Kerbel describes the steps that moved his career towards the angiogenesis field, the already achieved biological and clinical results and the unmet goals...
  10. ncbi request reprint Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers
    F Bertolini
    Division of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 12:987-90. 2001
    ..Although it has been reported that thalidomide significantly inhibits angiogenesis. it is still unclear whether its clinical effect is mediated, at least in part, by its anti-angiogenic properties...
  11. doi request reprint Response to anti-angiogenesis: an ever changing feature
    Francesco Bertolini
    Laboratory of Hematology Oncology, Department of Pathology, European Institute of Oncology, 20141 Milan, Italy
    Breast 20:S61-2. 2011
    ..However, the clinical benefit associated with the use of these drugs has been so far limited...
  12. ncbi request reprint The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer
    Francesco Bertolini
    European Institute of Oncology, Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Biochim Biophys Acta 1796:27-32. 2009
    ..The definition of CEC and CEP phenotype and the standardization of CEC and CEP enumeration strategies are highly desirable goals in order to exploit these cells as reliable biomarkers in oncology clinical trials...
  13. doi request reprint Biomarkers for angiogenesis and antiangiogenic drugs in clinical oncology
    Francesco Bertolini
    Laboratory of Hematology Oncology, European Institute of Oncology, Via Ripamonti 435, Milan, Italy
    Breast 18:S48-50. 2009
    ..However, identifying the best suited drug and the optimal dosage and schedule for treatment of patients remain challenging...
  14. ncbi request reprint The multifaceted circulating endothelial cell in cancer: towards marker and target identification
    Francesco Bertolini
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, 20141 Milan, Italy
    Nat Rev Cancer 6:835-45. 2006
    ....
  15. ncbi request reprint Molecular and cellular biomarkers for angiogenesis in clinical oncology
    Francesco Bertolini
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, 20141 Milan, Italy
    Drug Discov Today 12:806-12. 2007
    ..Here, we discuss the biological and technical facets of the search and validation of new biomarkers for angiogenesis...
  16. ncbi request reprint CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma
    Francesco Bertolini
    Divisions of Hematology Oncology, Experimental Oncology IFOM Institute of Molecular Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Cancer Res 62:3106-12. 2002
    ..Taken together, these data support clinical studies on CXCR4 neutralization in NHL patients by monoclonal antibodies or CXCR4 antagonists...
  17. doi request reprint Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate postresistance therapy
    Francesco Bertolini
    Departments of Pathology Laboratory Medicine and Medicine, Laboratory of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Biochim Biophys Acta 1806:131-7. 2010
    ....
  18. ncbi request reprint The thin red line: angiogenesis in normal and malignant hematopoiesis
    F Bertolini
    Division of Hematology Oncology, IRCCS European Institute of Oncology, Milan, Italy
    Exp Hematol 28:993-1000. 2000
    ..e., blood vessel generation from pre-existing vessels), together with recent findings about angiogenesis and antiangiogenic therapies in hematopoietic malignancies such as leukemia, lymphoma, myeloma, and myelodysplastic syndromes...
  19. ncbi request reprint Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells
    Francesco Bertolini
    Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Cancer Metastasis Rev 27:95-101. 2008
    ..Along with CECs and CEPs, potential EC- and CEP-related surrogate molecular markers such as VE-Cadherin and CD133 are currently under preclinical and clinical investigation...
  20. ncbi request reprint Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells
    Francesco Bertolini
    Division of Hematology Oncology, Department of Medicine, IFOM Fondazione Italiana per la Ricerca sul Cancro, Institute of Molecular Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Cancer Res 63:4342-6. 2003
    ..Our findings suggest that metronomic low-dose chemotherapy regimens are particularly promising for avoiding CEP mobilization and, hence, to potentially reduce vasculogenesis-dependent mechanisms of tumor growth...
  21. ncbi request reprint Circulating endothelial cells as a novel marker of angiogenesis
    Patrizia Mancuso
    Division of Hematology Oncology, European Institute of Oncology, and IFOM FIRC Institute of Molecular Oncology, Milan, Italy
    Adv Exp Med Biol 522:83-97. 2003
    ..Furthermore, this assay offers insight into anti-angiogenic activity of different drugs...
  22. doi request reprint Complementary populations of human adipose CD34+ progenitor cells promote growth, angiogenesis, and metastasis of breast cancer
    Stefania Orecchioni
    Authors Affiliations Laboratory of Hematology Oncology, Department of Pathology, and Division of Plastic Surgery, European Institute of Oncology and Division of Pathology, San Paolo University Hospital, Milan, Italy
    Cancer Res 73:5880-91. 2013
    ..Our findings suggest that adipose tissue progenitor cells cooperate in driving progression and metastatic spread of breast cancer...
  23. doi request reprint Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab
    Silvia Dellapasqua
    Medical Senology Research Unit, Department of Medicine, European Institute of Oncology, Milan, Italy
    Breast 21:309-13. 2012
    ..There is an urgent need for the identification of commonly assessable predictive factors in the treatment of patients with metastatic breast cancer...
  24. doi request reprint Circulating perivascular progenitors: a target of PDGFR inhibition
    Patrizia Mancuso
    Laboratory of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Int J Cancer 129:1344-50. 2011
    ..PPC enumeration might be studied as a tool for the definition of the optimal biologic dose of anti-PDGFR drugs and investigated clinically as a possible predictive/prognostic tool in patients receiving anti-PDGFR drugs...
  25. pmc Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy
    Patrizia Mancuso
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Blood 108:452-9. 2006
    ..005). Preclinical models indicated that the source of apoptotic CECs was most likely the tumor vasculature. CEC kinetics and viability are very promising as predictors of clinical response in patients undergoing metronomic chemotherapy...
  26. ncbi request reprint Stroma cells: a novel target of herceptin activity
    Chiara Corsini
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, 20141 Milan, Italy
    Clin Cancer Res 9:1820-5. 2003
    ..We investigated the activity of herceptin (HER), a humanized monoclonal antibody widely used for the treatment of HER2-overexpressing epithelial cancer, toward stroma cell lines L87/4 and L88/5...
  27. doi request reprint Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts
    Ines Martin-Padura
    Laboratory of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Lab Invest 92:952-66. 2012
    ..Therefore, combining a CD13 inhibitor, which targets the CSC-like population, with LDM-CTX chemotherapy may be used to eradicate minimal residual disease and improve the treatment of liver cancer...
  28. doi request reprint Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features
    Alessandra Balduzzi
    Research Unit of Medical Senology, European Institute of Oncology, Milan, Italy
    Anticancer Drugs 20:197-203. 2009
    ..A non-negligible rate of progressive disease was observed, suggesting careful monitoring of the patients. Further studies evaluating the potential benefit of bevacizumab in neoadjuvant treatment need to be tested...
  29. doi request reprint The white adipose tissue used in lipotransfer procedures is a rich reservoir of CD34+ progenitors able to promote cancer progression
    Ines Martin-Padura
    Laboratory of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Cancer Res 72:325-34. 2012
    ..Our results highlight the importance of gaining a better understanding of the role of different WAT-derived cells used in lipotransfer for breast reconstruction in patients with breast cancer...
  30. ncbi request reprint Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains
    Alice Agliano
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Int J Cancer 123:2222-7. 2008
    ..These models will be instrumental to studies on leukemia-initiating stem cells, leukemia biology, preclinical treatment studies, and to obtain patient-specific preclinical models to design and investigate patient-tailored therapies...
  31. doi request reprint Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity
    Emilia Montagna
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 12:207-14. 2012
    ..The analysis of the results suggests that the metronomic chemotherapy combined with bevacizumab and erlotinib is effective and well tolerated...
  32. ncbi request reprint Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors
    Manuela Capillo
    Department of Medicine, European Institute of Oncology, 20141 Milan, Italy
    Clin Cancer Res 9:377-82. 2003
    ....
  33. doi request reprint Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study
    Daniele Laszlo
    Department of Hematology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Clin Oncol 28:2233-8. 2010
    ....
  34. doi request reprint Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses
    Patrizia Mancuso
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Clin Cancer Res 15:267-73. 2009
    ..These cells are emerging as promising preclinical/clinical tools to define optimal biological doses of antiangiogenic therapies and to help stratify patients in clinical trials...
  35. ncbi request reprint Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index
    Giancarlo Pruneri
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    Int J Cancer 112:71-7. 2004
    ..Our data suggest that the t(6;14) translocation may be extremely uncommon in FL and that a deregulated expression of cyclin D3, possibly due to epigenetic mechanisms, may be involved in the pathogenesis of high-grade tumors...
  36. ncbi request reprint The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification
    Giancarlo Pruneri
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    J Pathol 206:337-45. 2005
    ..Our data suggest that TA-p63 is overexpressed in high-grade FL, possibly independent of the occurrence of gene abnormalities, and that it may be involved in the highly complex mechanism of regulation of apoptosis of FL cells...
  37. ncbi request reprint Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells
    Cristina Rabascio
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Cancer Res 64:4373-7. 2004
    ..Taken together, our data indicate that the quantitative evaluation of circulating VE-C RNA is a specific and highly promising tool with which to investigate the angiogenic phenotype of cancer patients...
  38. pmc Spontaneous cell fusion of acute leukemia cells and macrophages observed in cells with leukemic potential
    Ines Martin-Padura
    Laboratory of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Neoplasia 14:1057-66. 2012
    ....
  39. ncbi request reprint Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining
    Maurilio Ponzoni
    Department of Pathology, San Raffaele H Scientific Institute, Milan, Italy
    Mod Pathol 17:1513-20. 2004
    ..These findings provide a rationale for the investigational use of anti-CD105-targeted drugs in CIMF...
  40. pmc If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma
    Patrizia Mancuso
    Laboratory of Hematology Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    BMC Cancer 10:644. 2010
    ..BM immunophenotyping by flow cytometry (FC) is also used, although its clinical value is still under debate...
  41. ncbi request reprint Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer
    Pier Francesco Ferrucci
    Divisions of Hemato oncology and Biostatistics and Epidemiology, European Institute of Oncology, Milan, Italy
    Clin Cancer Res 10:6039-46. 2004
    ..The population on which the study was conducted was drawn from stage III breast cancer patients undergoing high-dose chemotherapy and autologous transplantation with PBPCCs...
  42. doi request reprint Circulating endothelial cells as biomarkers in clinical oncology
    Patrizia Mancuso
    Laboratory of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Microvasc Res 79:224-8. 2010
    ..The definition of CEC and CEP phenotype and the standardization of CEC and CEP enumeration procedures are highly warranted to use these cells as biomarkers in clinical trials in oncology, and to compare results from different studies...
  43. doi request reprint Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents
    Cristina Noberasco
    Clinical Pharmacology and New Drugs Development Unit, Department of Medicine, European Institute of Oncology, Milan, Italy
    Oncology 77:358-65. 2009
    ..alpha-Interferon, thalidomide and celecoxib inhibit tumour angiogenesis by differing mechanisms...
  44. pmc Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan
    Lucia Cuppini
    Department of Neuro Oncology Unit, Fondazione IRCCS Istituto Neurologico C, Besta, Milan, Italy
    PLoS ONE 8:e74345. 2013
    ....
  45. ncbi request reprint Skeletal muscle differentiation potential of human adult bone marrow cells
    Patrizia Bossolasco
    Fondazione Matarelli, Ospedale Fatebenefratelli e Oftalmico, Milan, Italy
    Exp Cell Res 295:66-78. 2004
    ..Further improvements might allow new approaches to cell-mediated therapies for muscular diseases...
  46. doi request reprint Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm
    Alice Agliano
    Laboratory of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Clin Cancer Res 17:6163-73. 2011
    ..Currently, more efforts are required to better define molecular and biological mechanisms associated with this pathology. To the best of our knowledge, no mouse model recapitulated human BNKL so far...
  47. doi request reprint Evaluation of circulating endothelial precursor cells in cancer patients
    Francesco Bertolini
    Laboratory of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Methods Mol Biol 904:165-72. 2012
    ..In this chapter, we describe a flow cytometry technique to detect CEPs obtained from human blood specimens stored in both fresh and frozen conditions...
  48. ncbi request reprint Circulating endothelial cell number and viability are reduced by exposure to high altitude
    Patrizia Mancuso
    Division of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Endothelium 15:53-8. 2008
    ..These data suggest a unique pattern of modulation of surrogate markers of vascular remodeling induced by exposure to hypobaric hypoxia...
  49. pmc Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma
    Federico Colombo
    Experimental Hepatology Laboratory, Centre of Transfusion Medicine, Cellular Therapy and Cryobiology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy
    PLoS ONE 6:e21369. 2011
    ..The aim of this study was to investigate and characterise tumour-propagating cell (TPC) compartments within human hepatocellular carcinoma (HCC)...
  50. ncbi request reprint Angiogenic cells, macroparticles and RNA transcripts in laparoscopic vs open surgery for colorectal cancer
    Anna Bono
    Department of Pathology Laboratory Medicine and Medicine, University of Milan, Milan, Italy
    Cancer Biol Ther 10:682-5. 2010
    ..Angiogenesis is crucial for tissue repair and cancer progression. We investigated a panel of angiogenic cells, macroparticles and RNA transcripts before, during and after laparoscopic colectomy or open colectomy for colorectal cancer...
  51. ncbi request reprint SP4, a novel anti-cyclin D1 rabbit monoclonal antibody, is a highly sensitive probe for identifying mantle cell lymphomas bearing the t(11;14)(q13;q32) translocation
    Giancarlo Pruneri
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    Appl Immunohistochem Mol Morphol 13:318-22. 2005
    ..0001). These data provide evidence that the SP4 monoclonal antibody may be a fast, easy-to-interpret, and reliable surrogate for the detection of the (11;14) translocation by molecular techniques...
  52. ncbi request reprint In vitro and in vivo hematopoietic potential of human stem cells residing in muscle tissue
    Chiara Dell'agnola
    Division of Hematology Oncology, Experimental Oncology IFOM FIRC Institute of Molecular Oncology, Pathology Laboratory Medicine, and Head and Neck Surgery, European Institute of Oncology, Milan, Italy
    Exp Hematol 30:905-14. 2002
    ..We studied the in vitro and in vivo hematopoietic potential of human stem cells residing in muscle tissue collected from adults with head and neck cancer...
  53. doi request reprint Circulating endothelial cells and circulating endothelial progenitors
    Patrizia Mancuso
    Laboratory of Hematology Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Recent Results Cancer Res 195:163-70. 2012
    ..The definition of CEC and CEP phenotypes and the standardization of CEC and CEP enumeration procedures are highly warranted to use these cells as biomarkers in clinical trials in oncology, and to compare results from different studies...
  54. ncbi request reprint Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma
    Giovanni Martinelli
    European Institute of Oncology, Milan, Italy
    Br J Haematol 123:271-7. 2003
    ..Based on our preliminary data, the combination of chlorambucil with rituximab seemed to be well tolerated and active. Its definitive role in the treatment of low-grade NHL should be further evaluated in randomized trials...
  55. ncbi request reprint Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat
    Daniele Laszlo
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Eur J Haematol 72:264-7. 2004
    ....
  56. ncbi request reprint Resting and activated endothelial cells are increased in the peripheral blood of cancer patients
    P Mancuso
    Division of Hematology-Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Blood 97:3658-61. 2001
    ..Blood. 2001;97:3658-3661)..
  57. ncbi request reprint Circulating endothelial cells as biomarkers for angiogenesis in tumor progression
    Ines Martin-Padura
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, 20141 Milan, Italy
    Front Biosci (Schol Ed) 1:304-18. 2009
    ..Thus, circulating CECs and CEPs may act as surrogate markers to test putative therapeutic efficacy. Moreover measuring CECs and CEPs may be useful to assess effects of antiangiogenic therapy...
  58. ncbi request reprint Strategies to investigate circulating endothelial cells in cancer
    Patrizia Mancuso
    Hematology Oncology, European Institute of Oncology, Milan, Italy
    Pathophysiol Haemost Thromb 33:503-6. 2003
    ....
  59. doi request reprint Miniaturized FISH for screening of onco-hematological malignancies
    Andrea Zanardi
    Tethis s r l, Milan, Italy
    Biotechniques 49:497-504. 2010
    ..Miniaturized FISH demonstrated comparable performance to standard FISH, indicating that it is suitable for genetic screenings, in research, and in clinical settings for the diagnosis of samples from onco-hematological malignancies...
  60. ncbi request reprint Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients
    Giancarlo Pruneri
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, School of Medicine, Italy
    Br J Haematol 118:817-20. 2002
    ..01), whereas there was no difference in survival between patients with low and high CD105+ MVD. Multivariate analysis confirmed the independent significant association between CD34+ MVD and survival (P = 0.001)...
  61. ncbi request reprint Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma
    F Bertolini
    Haematology Oncology, IRCCS European Institute of Oncology, Milan, Italy
    Br J Haematol 106:504-9. 1999
    ..Our data suggest that b-FGF and, particularly, VEGF might be considered prognostic factors in NHL staging and management...
  62. ncbi request reprint Angiogenesis occurs in hairy cell leukaemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna-12
    Giancarlo Pruneri
    Divisions of Pathology and Laboratory Medicine, University of Milan School of Medicine, Italy
    Br J Haematol 120:695-8. 2003
    ..The BM tumour burden significantly decreased in patients treated with interferon-alpha, but the mean value of MVD remained unchanged. These data suggest that angiogenesis may be involved in the pathogenesis of HCL...
  63. ncbi request reprint Idarubicin containing regimen in multiple myeloma: preliminary results of a pilot study using a modified "TANDEM" transplant program
    G Martinelli
    Department of Hematology Oncology, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy
    Leuk Lymphoma 44:299-302. 2003
    ..This approach could reduce the toxic effects and maintain the efficacy of therapy at the same time...
  64. ncbi request reprint Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or exten
    G Curigliano
    Department of Medicine, Division of Medical Oncology, Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milano, Italy
    Breast Cancer Res Treat 93:35-40. 2005
    ..To assess if feature, extent and duration of surgery could influence levels of systemic proangiogenic cytokines vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and transforming growth factor beta (TGF-beta)...
  65. ncbi request reprint The prevalence and clinical implications of c-kit expression in plasma cell myeloma
    G Pruneri
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan, School of Medicine, Italy
    Histopathology 48:529-35. 2006
    ..To evaluate the clinical implications of c-kit (CD117) expression in plasma cell myeloma (PCM)...
  66. ncbi request reprint A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer
    P F Ferrucci
    Division of Hemato Oncology, European Institute of Oncology, I 20141 Milan, Italy
    Int J Oncol 30:955-62. 2007
    ..06) respectively. These data confirm the activity of MAM as a negative prognostic factor and show for the first time that MAS could work as a tumor suppressor gene even in a clinical setting, since it protects from recurrence...
  67. doi request reprint Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chlor
    C Rabascio
    Dept of Haematology, European Institute of Oncology, Via Ripamonti 435, 20141 Milano, Italy
    Leuk Res 34:454-7. 2010
    ..In vitro studies of resistant human cell lines have confirmed that human concentrative nucleoside transporter 1 (hCNT1)-deficient cells display resistance...
  68. pmc Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity
    R Torrisi
    Department of Medicine, Research Unit of Medical Senology, European Institute of Oncology Milan, Milan, Italy
    Br J Cancer 99:1564-71. 2008
    ..In conclusion, bevacizumab is feasible and active in association with primary chemoendocrine therapy for ER-positive tumours in terms of proliferation inhibition, clinical response and antiangiogenic activity...
  69. ncbi request reprint Cyclin D3 immunoreactivity in gastrointestinal stromal tumors is independent of cyclin D3 gene amplification and is associated with nuclear p27 accumulation
    Giancarlo Pruneri
    Division of Pathology, European Institute of Oncology, Milan, Italy
    Mod Pathol 16:886-92. 2003
    ..066) only. These data suggest that cyclin D3 expression in GISTs is independent of gene amplification and that this protein may be involved in the pathogenesis of GISTs by counteracting the inhibitory activities of p27...
  70. doi request reprint Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice
    Svetlana Gingis-Velitski
    Department of Molecular Pharmacology, Rappaport Faculty of Medicine, Technion, Haifa, Israel
    Cancer Res 71:6986-96. 2011
    ..Taken together, our findings illustrate how some chemotherapies can exert prometastatic effects that may confound treatment outcomes...
  71. doi request reprint Simultaneous characterization of progenitor cell compartments in adult human liver
    Laura Porretti
    Center of Transfusion Medicine, Cellular Therapy and Cryobiology, IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy
    Cytometry A 77:31-40. 2010
    ..We also optimized a flow cytometry approach that will be useful in exploring the contribution of these cells to the pathogenesis of liver disease...
  72. ncbi request reprint Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma
    F Bertolini
    Divisions of Hematology Oncology, Experimental Oncology, and Pathology Laboratory Medicine, IRCCS European Institute of Oncology, Milan, Italy
    Blood 96:282-7. 2000
    ..In conclusion, sequential administration of chemotherapy and endostatin seems promising for treating bulky NHL, and the less toxic sequential administration of rituximab and endostatin is promising for treating limited disease. (..
  73. ncbi request reprint Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma
    S Monestiroli
    Division of Hematology-Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Cancer Res 61:4341-4. 2001
    ..Conversely, in mice given endostatin, all of the increase in apoptotic cells was in the endothelial cell compartment. CEC evaluation is promising as a noninvasive, surrogate angiogenesis marker...
  74. ncbi request reprint The circulating endothelial cell in cancer: towards marker and target identification
    I Martin-Padura
    Division of Hematology Oncology, Department of Medicine, IEO European Institute of Oncology, Milan, Italy
    Curr Pharm Des 14:3780-9. 2008
    ..On the basis of these observations, CEC and CEP measurements have attractive potential diagnostic and therapeutic applications for malignant diseases...
  75. ncbi request reprint Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings
    Filiberto Belli
    Unit of General Surgery 2, Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 20:4169-80. 2002
    ....
  76. ncbi request reprint Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma
    M Iavarone
    AM and A Migliavacca Center for Liver Diseases, Department of Gastroenterology and Endocrinology, IRCCS Maggiore Hospital Fondazione Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    J Viral Hepat 14:133-9. 2007
    ..There was a gradient of VEGF-165 between hepatic and femoral veins in both HCC and cirrhosis. In conclusion, VEGF appears to be involved in the development of HCC and it could be a predictor of HCC development in patients with cirrhosis...
  77. pmc Angiogenesis in myelodysplastic syndromes
    G Pruneri
    Second Division of Pathology, IRCCS Maggiore Hospital, Milan, Italy
    Br J Cancer 81:1398-401. 1999
    ..Since our findings suggest a correlation between angiogenesis and progression to leukaemia, additional work is now warranted to determine what regulates the generation of new vessels in MDS and leukaemia...
  78. ncbi request reprint Hepatocyte-conditioned medium sustains endothelial differentiation of human hematopoietic-endothelial progenitors
    Veronica Bordoni
    National Institute for Infectious Diseases L Spallanzani, IRCCS, Rome, Italy
    Hepatology 45:1218-28. 2007
    ....
  79. ncbi request reprint Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation
    Giancarlo Pruneri
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan, School of Medicine, Italy
    Hum Pathol 34:41-7. 2003
    ..Our data suggest that the immunohistochemical evaluation of p53 IR in bone marrow biopsies may represent an adjunct in MM patient prognostication...
  80. ncbi request reprint Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34- human stem cells
    Roberto M Lemoli
    Istituto di Ematologia e Oncologia Medica L and A Seragnoli, University of Bologna, Bologna, Italy
    Br J Haematol 123:720-9. 2003
    ..Thus, our study indicated that CD34 expression on human PB stem cells was associated with haematopoietic activity, cell-cycle recruitment and downregulation of p27Kip1 in vitro and higher engraftment capacity in vivo...
  81. ncbi request reprint On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent
    Yuval Shaked
    J Clin Oncol 24:4040; author reply 4040-1. 2006
  82. pmc Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
    Yuval Shaked
    Sunnybrook and Women s College Health Sciences Centre, Molecular and Cellular Biology Research, Department of Medical Biophysics, University of Toronto, Ontarip, Canada
    Blood 106:3058-61. 2005
    ..These results suggest that CEPs may serve as a pharmacodynamic biomarker to determine the OBD of metronomic chemotherapy regimens...
  83. ncbi request reprint The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration
    Lara Rossi
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, and Stem Cell Research Center, S Orsola Malpighi Hospital, Italy
    Blood 109:533-42. 2007
    ..Our data suggest that UTP may physiologically modulate the homing of HSCs to the BM, in concert with CXCL12, via the activation of converging signaling pathways between CXCR4 and P2Y receptors, involving Galphai proteins and RhoGTPases...
  84. ncbi request reprint Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose
    Yuval Shaked
    Molecular and Cellular Biology Research, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    Curr Cancer Drug Targets 5:551-9. 2005
    ..Finally, another promising marker we discuss is soluble VEGFR-2...
  85. ncbi request reprint Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis
    Yuval Shaked
    Department of Molecular and Cellular Biology, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario M3N 4M5, Canada
    Cancer Cell 7:101-11. 2005
    ..Finally, treatment with a targeted VEGFR-2 antibody caused a dose-dependent reduction in viable CEPs that precisely paralleled its previously and empirically determined antitumor activity...
  86. pmc Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents
    Yuval Shaked
    Molecular and Cellular Biology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada
    Cancer Cell 14:263-73. 2008
    ....
  87. doi request reprint Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis
    Giancarlo Pruneri
    Leuk Res 32:1628-32. 2008
  88. ncbi request reprint Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model
    Haiqing Li
    Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    BJU Int 101:884-8. 2008
    ....
  89. pmc Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas
    Robert S Kerbel
    Proc Natl Acad Sci U S A 105:E54; author reply E55. 2008
  90. ncbi request reprint Circulating endothelial cells. Biomarker of vascular disease
    Andrew D Blann
    Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, B18 7QH, UK
    Thromb Haemost 93:228-35. 2005
    ..The objective of the present communication is to condense existing data on CECs, briefly compare them with progenitor cells, and summarise possible mechanism(s) by which they may contribute to vascular pathology...
  91. ncbi request reprint Stem cell plasticity: time for a reappraisal?
    Roberto M Lemoli
    Istituto di Ematologia e Oncologia Medica L e A Seragnoli, Universita di Bologna, Bologna, Italia
    Haematologica 90:360-81. 2005
    ..In addition to the authors' own work, the present review examines articles published in journals covered by the Science Citation Index and Medline...
  92. ncbi request reprint Autologous peripheral blood stem cell transplantation for myocardial regeneration: a novel strategy for cell collection and surgical injection
    Giulio Pompilio
    Department of Cardiovascular Surgery, Centro Cardiologico Monzino IRCCS, Milano, Italy
    Ann Thorac Surg 78:1808-12. 2004
    ..Bone-marrow and peripheral blood-derived stem cells can be used as stimulators of myogenesis and angiogenesis. We describe an original technique for collection and surgical intramyocardial injection of peripheral blood-derived stem cells...
  93. ncbi request reprint Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo
    Roberto M Lemoli
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Italy
    Blood 104:1662-70. 2004
    ..Our data suggest that extracellular nucleotides may provide a novel and powerful tool to modulate HSC functions...
  94. ncbi request reprint Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research
    Francesco Bertoni
    Experimental Oncology, Oncology Institute of Southern Switzerland, Via Vincenzo Vela 6, Stabile IRB, 6500 Bellinzona, Switzerland
    Br J Haematol 124:289-98. 2004
    ..2 and 11q23.2. There was no association between 11q loss and IgH gene somatic mutation rate; the use of VH3-21 gene could be associated with a better prognosis...
  95. ncbi request reprint Chimerism of the transplanted heart
    Francesco Bertolini
    N Engl J Med 346:1410-2; author reply 1410-2. 2002